EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development

Alessandra Serra iD, Julia Geronimi, Sandrine Guilleminot, Hugo Hadjur, Marie-Karelle Riviere, Gaëlle Saint-Hilary, Pavel Mozgunov iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70026 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Alessandra Serra and 6 co-authors. Institution: University of Cambridge, MRC Biostatistics Unit, Cambridge, UK. Major MEDLINE topics: Biomarkers, Drug Development. Cited 4 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research, Medical Research Council.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Identifying and quantifying predictive biomarkers is a critical issue of personalized medicine approaches and patient‐centric clinical development strategies. In early stages of the development process, significant challenges and numerous uncertainties arise. One of the challenges is the ability to assess the predictive value of a biomarker, i.e., the difference in primary outcomes between experimental and placebo arms above and below a certain threshold of the biomarker. Indeed, when the accumulated information is very limited and the sample size is small, preliminary conclusions about the predictive properties of the biomarker might be misleading. To date, the majority of investigations regarding the predictiveness of biomarkers were in the setting of moderate‐to‐large sample sizes. In this work, we propose a novel flexible approach inspired by the Kolmogorov‐Smirnov Distance in order to assess the predictiveness of a continuous biomarker in a clinical setting where the sample size is small. Via simulations we show that the proposed method allows to achieve a higher power to declare predictiveness compared to the existing methods under a range of scenarios, whilst still maintaining a control of the type I error at a pre‐specified level.

Subjects

MeSH terms (MEDLINE)

BiomarkersDrug DevelopmentHumansComputer SimulationSample SizePrecision MedicineModels, StatisticalStatistics, NonparametricPredictive Value of Tests

Author keywords

continuous biomarkerearly phasepersonalized medicinepredictive

Substances

Biomarkers

Authors and institutions

  • University of Cambridge, MRC Biostatistics Unit, Cambridge, UK.
  • Institut de Recherches Internationales Servier, Gif-sur-Yvette, France.
  • Department of Statistical Methodology, Saryga, Tournus, France.

ORCID profiles: Alessandra Serra, Pavel Mozgunov

Funding

  • National Institute for Health and Care Research
  • Medical Research Council

Cite

APA

Serra, A., Geronimi, J., Guilleminot, S., Hadjur, H., Riviere, M. K., Saint-Hilary, G., & Mozgunov, P. (2025). A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development. Statistics in Medicine. https://doi.org/10.1002/sim.70026

Vancouver

Serra A, Geronimi J, Guilleminot S, Hadjur H, Riviere MK, Saint-Hilary G, et al. A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development. Statistics in Medicine. 2025. doi:10.1002/sim.70026

BibTeX
@article{Serra2025,
  author = {Serra, Alessandra and Geronimi, Julia and Guilleminot, Sandrine and Hadjur, Hugo and Riviere, Marie-Karelle and Saint-Hilary, Gaëlle and Mozgunov, Pavel},
  title = {A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70026}
}
Start for free →